We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Gene Therapy in Patients With Mucopolysaccharidosis Disease

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03173521
Recruitment Status : Active, not recruiting
First Posted : June 2, 2017
Last Update Posted : December 6, 2021
Sponsor:
Information provided by (Responsible Party):
Fondazione Telethon

Brief Summary:
This study investigated the safety and efficacy of gene therapy approaches for Mucopolysaccharidosis type VI disease caused by the deficiency of arylsulfatase B (ARSB) enzyme. The aim of the study is to evaluate the safety and efficacy of the treatment.

Condition or disease Intervention/treatment Phase
Mucopolysaccharidosis Type VI Biological: AAV2/8.TBG.hARSB Phase 1 Phase 2

Detailed Description:
Mucopolysaccharidosis type VI disease is involved in Lysosomal Storage Disorder. The MPS VI disease is characterized by growth retardation, corneal clouding, cardiac valve disease, organomegaly, skeletal dysplasia, without central nervous system involvement.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 9 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Intervention Model Description: Open Label
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase I/II Open Label, Dose Escalation, Safety Study in Subjects With Mucopolysaccharidosis Type VI (MPS VI) Using Adeno-Associated Viral Vector 8 to Deliver the Human ARSB Gene to Liver
Actual Study Start Date : July 17, 2017
Estimated Primary Completion Date : June 30, 2025
Estimated Study Completion Date : September 30, 2025


Arm Intervention/treatment
Experimental: open label

Adeno-associated viral vector serotype 8 with liver-specific thyroxine-binding globulin (TBG) promoter driving the expression of the human ARSB gene diluted in its final formulation medium [Drug product (DP) diluted in 0.9% saline solution and 0.25% of human serum albumin].

Four dose levels are available:

  • 'Starting dose' is 6x1011 gc of vector per kg of body weight.
  • 'High dose' is 2x1012 gc of vector per kg of body weight.
  • 'Very high dose' is 6x1012 gc of vector per kg of body weight.
  • 'Low dose' is 2x1011 gc of vector per kg of body weight. Intermediate doses are also possible. The administration of the IMP will be performed into a peripheral vein (e.g. median cubital vein) over 2-4 hours using an infusion pump. The IMP final volume to be injected is calculated based on the patient's weight (determined on the day of hospital admission), as 3 mL/kg.
Biological: AAV2/8.TBG.hARSB

Adeno-associated viral vector serotype 8 with liver-specific thyroxinebinding globulin (TBG) promoter driving the expression of the human ARSB gene. Four dose levels are available:

  • Starting dose is 6x1011 gc of vector per kg of body weight;
  • High dose is 2x1012 gc of vector per kg of body weight and will be administered after at least two subjects at the starting dose have experienced no DLT;
  • Very high dose is 6x1012 vector per kg of body weight and will be administered after three subjects at the high dose have experienced no DLT;
  • Low dose is 2x1011 gc of vector per kg of body weight. Intermediate doses are also possible. The administration of the IMP will be performed into a peripheral vein. The IMP final volume to be injected is calculated based on the patient's weight (determined on the day of hospital admission), as 3 mL/kg.




Primary Outcome Measures :
  1. Safety and tolerability of the IMP administration [ Time Frame: From GT up to 5 years post IMP administration at the following visits: days 1,2,3; weeks 2,3,6,7,8,9,10,11,12,13,14; months 4,9,12; years 1.5, 2, 2.5, 3, 3.5, 4, 4.5, 5. ]
    Overall safety and tolerability will be determined through monitoring of adverse events, laboratory and clinical investigations and imaging studies (for example complete physical examination with vital signs recording, liver ultrasound, measurement of transaminases, thyroids hormones, creatinine, albumin, total proteins in blood and urine, and urea, C3 and C4 in blood).

  2. Primary efficacy outcome - Urinary GAG levels [ Time Frame: From GT up to 5 years post IMP administration at the following visits: days 1,2,3; months 4,9,12,15; years 1.5,1.75, 2, 2.5, 3, 4, 5. ]
    To determine the efficacy of gene therapy, post-injection urinary GAG excretion levels will be compared to the average of pre-injection urinary GAG determined at baseline 1 and at visit 1.


Secondary Outcome Measures :
  1. Secondary efficacy outcome - endurance [ Time Frame: From GT up to 5 years post IMP administration at the following visits: months 4,9,12; years 1.5, 2, 2.5, 3. ]
    Endurance as measured by 6-minute walk test (6MWT) in walking subjects, 3-minute stair climb test (3MSCT) in walking subjects.

  2. Secondary efficacy outcome - lung volumes [ Time Frame: From GT up to 5 years post IMP administration at the following visits: months 4,9,12; years 1.5, 2, 2.5, 3. ]
    Forced vital capacity (FVC), and forced expiratory volume at 1 second (FEV1) in cooperative subjects.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   4 Years to 65 Years   (Child, Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Documented biochemical and molecular diagnosis of MPS VI. Testing for homozygous or compound heterozygous disease-causing mutations of the ARSB gene must have been performed by an accredited laboratory.
  2. Subjects must be of 4 years of age or older.
  3. Subjects should have received ERT for at least 12 months before enrolment and should continue to receive ERT until 7-14 days before IMP administration.
  4. Documented informed consent; willingness to adhere to protocol and to participate to long-term follow-up, as evidenced by written informed consent.

Exclusion Criteria:

  1. Subjects unable or unwilling to meet requirements of the study.
  2. Participation in a clinical study with an investigational drug in the 6 months prior to enrolment in this trial.
  3. Subjects unable to perform the 6MWT.
  4. History of severe anaphylactoid reaction to Naglazyme in subjects receiving ERT that could affect the safety (severe reaction is meant to be a respiratory impairment event that is life-threatening).
  5. Presence of tracheostomy or need of ventilatory assistance.
  6. Subjects with evidence of progressive myelomalacia that is considered severe enough to require neck surgery in the first six months after enrolment.
  7. Values of AST or ALT above the upper limit of normal range at baseline 2 (at -5days) evaluations.
  8. Co-existence of chronic diseases or clinically relevant abnormal baseline laboratory values; infections with hepatitis B, C, or HIV (Baseline 1).
  9. Systemic corticosteroid therapy or other immunosuppressive/immunomodulating drugs within 2 months prior to IMP administration.
  10. Female individuals of childbearing age who are pregnant or nursing or unwilling to use effective contraception for at least one year post-IMP administration.
  11. Fertile male individuals who are unwilling to use male barrier contraceptives such as condom.
  12. Any other condition that would not allow the subject to complete follow-up examinations during the course of the study and that, in the opinion of the Investigator, would make the subject unsuitable for the study.
  13. Presence of serum NAB to AAV8 above the limit of detection of the assay (Screening and Baseline 1).
  14. Presence of serum antibodies anti-ARSB above the upper limit of detection of the assay (antibodies anti-ARSB level >31250 or declared positive at the value of serum dilution 1.10 according to the performed assay) at Screening and Baseline 1.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03173521


Locations
Layout table for location information
Italy
Department of Translational Medicine (DISMET) of "Federico II" University, Naples
Naples, Italy, 80131
Turkey
Children's Hospital Hacettepe University
Ankara, Turkey
Sponsors and Collaborators
Fondazione Telethon
Investigators
Layout table for investigator information
Principal Investigator: Nicola Brunetti-Pierri Department of Translational Medicine (DISMET) of "Federico II" University, Naples
Layout table for additonal information
Responsible Party: Fondazione Telethon
ClinicalTrials.gov Identifier: NCT03173521    
Other Study ID Numbers: TIGEM1-MPS VI
First Posted: June 2, 2017    Key Record Dates
Last Update Posted: December 6, 2021
Last Verified: November 2021

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by Fondazione Telethon:
MPSVI
Additional relevant MeSH terms:
Layout table for MeSH terms
Mucopolysaccharidoses
Mucopolysaccharidosis VI
Carbohydrate Metabolism, Inborn Errors
Metabolism, Inborn Errors
Genetic Diseases, Inborn
Lysosomal Storage Diseases
Mucinoses
Connective Tissue Diseases
Metabolic Diseases